Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial)
© Hu et al.; licensee BioMed Central Ltd. 2013
Received: 18 August 2012
Accepted: 28 January 2013
Published: 15 February 2013
Lung cancer is still the leading cause of cancer-related mortality worldwide. Around 80 to 85% of lung cancers are non-small cell lung cancer (NSCLC). Regional lymphatic metastasis is a frequent occurrence in NSCLC, and the extent of lymphatic dissemination significantly determines the prognosis of patients with NSCLC. Hence, identification of alternative treatments for these patients should be considered a priority. Liposomal paclitaxel is a new formulation composed of paclitaxel and liposomes, with favorable pharmacokinetic properties. In particular, it produces dramatically higher drug concentrations in the lymph nodes than occurs with the current formulations of paclitaxel, thus we believe that patients with NSCLC with regional lymphatic metastasis may benefit from this new drug. Cisplatin-based doublet chemotherapy is recommended as the first-line treatment for patients with advanced NSCLC. We have designed a trial to assess whether first-line chemotherapy using liposomal paclitaxel combined with cisplatin (LP regimen) is superior to gemcitabine combined with cisplatin (GP regimen) in efficacy (both short-term and long-term efficacy) and safety (adverse events; AEs).
This is a prospective, open-label, controlled randomized clinical trial (RCT) to assess the therapeutic effects and safety of liposomal paclitaxel. The study aims to enroll 126 patients, who will be randomly allocated to one of the two treatment groups (LP and GP), with 63 patients in each group. Patients will receive four to six cycles of the assigned chemotherapy, and primary outcome will be assessed every two cycles. Patients will be recommended for surgery if the tumor becomes resectable. All participants will be followed up for at least 12 months. The objective response rate (ORR), changes in regional lymphatic metastasis (including number and size) and TNM (tumor, node, metastasis) staging will be the primary outcome measures. Progression-free survival, objective survival, median survival time, 1-year survival rate, toxicity, and time to disease progression will be the secondary outcome measures.
A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis.
http://www.chictr.org Identifier: ChiCTR-TRC-12602105
KeywordsLiposomal paclitaxel Cisplatin Gemcitabine Regional lymph node metastasis Trials
Regional lymphatic metastasis was generally involved in patients with NSCLC
Lung cancer has become the leading cause worldwide of cancer-related mortality in both men and women . Around 80 to 85% of lung cancers are non-small cell lung cancer (NSCLC), adequate therapeutic planning is largely dependent upon early diagnosis, and surgery is still the preferred treatment for early-stage tumors . However, it is known that approximately 70% of patients with NSCLC have advanced local invasion and/or distant metastasis at the time of diagnosis, and thus surgery is not possible for these patients. Presence of regional lymphatic metastasis is generally found in NSCLC even in the early stages of tumor growth, partly because of the wide distribution of lymphoid tissue in the lung, and also because the extent of lymphatic dissemination also significantly determines the clinical prognosis for patients with NSCLC . Therefore, therapeutic strategies focusing on the issue of regional lymphatic metastasis are of great importance not only for the control of distant lung-cancer metastases, but also for reducing the TNM (tumor, node, metastasis) stage and thus regaining the opportunity for surgery.
Currently, cisplatin-based doublet chemotherapy consisting of cisplatin combined with third-generation drugs (paclitaxel, gemcitabine, vinorelbine, or docetaxel) is commonly recommended as the standard treatment for patients with advanced NSCLC [4–7]. However, the pharmaceutical properties of the drugs or formulations, including poor drug permeability through cell membranes or tissue barriers, short circulating half-life, and rapid metabolism, heavily influence the effectiveness of tumor therapy . Consequently, use of chemotherapy drugs targeting regional lymph nodes remains to be further explored and evaluated.
The specific pharmaceutical properties of liposomal paclitaxel
Paclitaxel is a complex diterpenoid natural product, which has become a first-line treatment for NSCLC. However, because of its poor water solubility, paclitaxel has been used in an encapsulated form with the organic co-solvents ethanol and polyethoxylated castor oil (a formulation marketed as Taxol®; Bristol-Myers Squibb, New York, NY, USA) for clinical trials, but has been shown to cause toxic effects, including life-threatening anaphylaxis . Liposomal paclitaxel (Lipusu; Luye Pharma Group Ltd., Nanjing, China) is a new formulation of paclitaxel and phosphatidylcholine liposomes. Pharmacokinetic studies in animal models [10–12] have shown that, compared with the current paclitaxel formulation, liposomal paclitaxel has a significantly prolonged elimination half-life and mean retention time, and an apparent larger volume of distribution. Even more unexpected and exciting is that the concentration of liposomal paclitaxel in tissues is dramatically higher than that of paclitaxel, especially in the reticuloendothelial system, including the lymph nodes, liver, and spleen. Several clinical studies [12–17] recently indicated that the efficacy of liposomal paclitaxel equaled or slightly exceeded that of the current paclitaxel (Taxol®) formulation, while having a superior safety profile.
Hypothesis and study basis
We searched MEDLINE (from 1968 to 2012), EMBASE (from 1977 to 2012), and the Cochrane Library (from 1953 to 2012), using selected key words including ‘liposomal paclitaxel (or paclitaxel liposomes)’, ‘lung cancer (or NSCLC)’, ‘lymphatic metastasis’ and ‘controlled trial (or RCT)’. We did not find any clinical randomized controlled trial (RCT) to date that had examined the role of liposomal paclitaxel in patients with NSCLC with regional lymphatic metastasis. The RCTs performed thus far have focused on patients with advanced NSCLC as a whole. In view of the pharmacokinetic characteristics of liposomal paclitaxel in lymph nodes, we speculate that this new formulation may represent a novel chemotherapy drug, and could play a unique role in the treatment of NSCLC with regional lymphatic metastasis. In this paper, we outline our proposed protocol for a prospective open-label RCT aimed at testing this hypothesis.
This clinical trial aims to determine whether first-line therapy using liposomal paclitaxel combined with cisplatin (LP regimen) is more effective and safer than gemcitabine combined with cisplatin (GP regimen) for patients with NSCLC with regional lymphatic metastasis.
Phase 1 (recruitment and assignment of patients). Consenting eligible participants will be recruited in accordance with the inclusion/exclusion criteria and assigned randomly to one of the two treatment groups.
Phase 2 (chemotherapy). Patients will receive four to six cycles of chemotherapy with either LP or GP. Adverse events (AEs) will be rigorously monitored and recorded on a case report form (CRF).
Phase 3 (follow-up). Patients will be followed up for at least 12 months.
The study has been approved by the ethics committee of The First Affiliated Hospital of Third Military Medical University (No: KY201006), and is registered at ChiCTR (Chinese Clinical Trial Registry, trial Identifier ChiCTR-TRC-12602105). All study participants will provide written informed consent before participation.
Hospitalized patients, both male and female, aged 18 to 75 years.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Pathological diagnosis of non-small cell lung cancer, TNM stage III to IV.
Patients have never received any other chemotherapy.
In accordance with Response Evaluation Criteria in Solid Tumors (RECIST) (RECIST)/WHO evaluation criteria , at least one lesion, measurable or evaluable, should be detected by chest CT, and regional lymph-node metastasis should also be measurable or evaluable (including neck and supraclavicular lymph-node metastasis).
Expected survival ≥ 3 months.
Hematology, liver and kidney function are normal, the blood and biochemical indicators should meet the following criteria:
Bone marrow: absolute neutrophil count (ANC) ≥ 1.5 × 109/l (1500/mm3)
White blood cell count (WBCC) ≥ 4000 / mm3
Platelet count ≥ 100,000 / mm3
Hemoglobin ≥ 9 g/dl
Liver: serum bilirubin ≤ 2 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN (or ≤ 5 times normal limit for ALT and AST if liver metastasis present)
Kidney: serum creatinine ≤ 1.5 times ULN.
Good understanding and compliance by patients with the pilot program, and provision of informed consent.
Allergy to drugs.
Pregnancy or lactation.
History of cardiovascular disease (CVD), including congestive heart failure (higher than New York Heart Association level II).
Presence of unstable angina (resting angina symptoms) or new onset of angina (in the previous 3 months) or myocardial infarction (in the previous 6 months).
Presence of severe organic disease, including active infection or CVD.
Poor hepatic function or severe cirrhosis.
Abnormal blood coagulation indicators.
Poor condition or cachexia.
Receipt of radiotherapy or other local physical therapy within the previous 6 months.
Receipt of other anti-cancer treatment (such as chemotherapy, radiotherapy, immunosuppressive agents, chemoembolization, or targeted agents).
Recent (1 day to 4 weeks) participation in another clinical drug trial.
Other exclusion criteria: presence of other factors that might lead to failure to participate in or complete the clinical study (such as mental illness or drug abuse), or might affect the analysis of results.
Ongoing recruitment will continue for a maximum of 12 months (between June 2012 and June 2013) or until 126 individuals have been randomly assigned. The full study is expected to be finished before December 2014, when all the patients will have been followed up for at least 12 months.
Baseline examinations before treatment
Medical history and demographic information, including sex, age, address, and telephone details.
Physical examination: height, weight, body surface area, and vital signs, including heart rate, blood pressure, respiration rate, and temperature.
Laboratory examinations: routine blood and urine tests, liver and renal function.
Electrocardiography (ECG) and chest computed tomography (CT) scans.
The above examinations should be performed at least 1 week before chemotherapy begins. Tumors should be evaluated on the basis of the tumor-associated symptoms, physical examination of the superficial lesions, and results of imaging studies.
Examinations during treatment
Physical status, physical examination, routine blood and urine tests, liver and renal function tests, and ECG should be performed 2 to 3 days before each chemotherapy cycle.
Routine blood tests will be performed on days 4, 8, and 14 after each cycle of chemotherapy. The times will be increased if myelosuppression happens.
During the treatment, tumor will be evaluated 1 week after every two cycles of chemotherapy, as described above.
After treatment, participants will be required to return to our department for follow-up every 4 months, at which time repeat chest CT will be performed. Patients will be informed that they should contact us immediately if AEs occur, and in such cases, any relevant examinations needed for treatment will be undertaken.
Chemotherapy procedure of both groups
Route of administration
135 to 175 mg/m2 in saline (500 ml)1
IV drip (over 3 hours)
75 mg/m2 in saline (500 ml)2
1 and 8
1000 mg/m2 in saline (100 ml)
IV drip (over 30 min)
75 mg/m2in saline (500 ml)2
The chemotherapy will be given as four to six cycles in total, with every 21 days making up one cycle. One week after every two cycles, the efficacy should be evaluated in accordance with the RECIST criteria . The chemotherapy should go on as long as the efficacy evaluation indicates complete response (CR), partial response (PR), or stable disease. Surgery will be suggested if the TNM stage of the tumor reduces sufficiently for the lesion to become resectable; in such cases, the relevant chemotherapy regimen will continue after surgery.
Assuming that there is a normal proportion of granulocytes, the chemotherapy will be allowed to continue if the WBCC is within the range of 3.0 to 4.0 × 109/l. If the WBCC falls within the range of 2.0 to 3.0 × 109/l, chemotherapy will be stopped until the WBCC increases to 3.0 × 109/l, or above. Granulocyte colony-stimulating factor will be used for supportive treatment if WBCC decreases to 2.0 × 109/l or below.
The doses of chemotherapy drugs will be decreased by 25% in the next cycle if IV degree toxicity (including fever-induced neutropenia syndrome) emerges. Chemotherapy will be stopped in advance in cases of disease progression, or unacceptable AEs,,even the patient may not finish the chemotherapy plan.
Primary and secondary outcome measures
Objective response rate (ORR): total of CR + PR.
Change in regional lymphatic metastasis (including number and size).
Change in TNM staging.
Efficacy will be evaluated every two cycles, with chest CT performed 4 weeks after each evaluation to confirm if the result is CR or PR.
Median survival time.
Survival rate at 1 year.
Time to disease progression.
Follow-up will consist of a telephone survey and a visit to the clinic for re-examination. Chest CT will be performed every 4 months. All patients will be followed up for at least 12 months.
Reporting of adverse events
Participants will be requested to report any AEs occurring at any point throughout the whole trial, and the doctors will give appropriate advice. All AEs will be recorded in detail by the researchers, using a questionnaire that includes the following.
Description of the AE and associated symptoms.
When did the AE happen?
What was the severity of the AE?
How long did the AE last?
What steps did the doctor or patient take after the AE?
What was the outcome of the AE?
The severity of the AE will be graded using National Cancer Institute Common Toxicity Criteria (NCICTC,3rd edition) for drug-associated AEs. Any AEs not included in the classification will be evaluated using a four-grade scale: I (mild), 2 (moderate), 3 (severe), and 4 (extremely severe, i.e. life-threatening).
Severe AEs will be reported to the local authorities within 24 hours, in accordance with the relevant procedures.
where p t is the objective response rate of the LP group (65%), p c is the objective response rate of the GP group (35%), and is the average response rate of both groups: (65% + 35%)/2 = 50%. The sample size is then calculated as: n1 = n2 ≈ 57.
Allowing a 10% drop-out rate during the study, we have estimated that 63 patients will need to be enrolled in each group, that is, 126 patients in total. Intention-to-treat (ITT) analysis will be applied to minimize bias due to drop-outs.
Participants who satisfy the inclusion/exclusion criteria will be randomized in a 1:1 ratio using a computer-generated randomization number table at an independent department (Center of Evidence-Based Medicine and Clinical Epidemiology) who will not take part in the following enrollment. To guarantee correct randomization, the patient identification number and treatment allocation will be provided by a central telephone-based randomization system. After the patient's eligibility for enrollment has been assessed, a unique randomization number will be sent to our department through this central randomization system, and the patient will be assigned to the appropriate treatment group, thus each group will be allocated 63 participants. To minimize the possibility of bias in reporting and assessing the endpoints, the trial will use a PROBE (Prospective Randomized Open trial with Blinded Evaluation of outcomes) design.
Data collection and statistical analysis
Codes will be used to guarantee the privacy of the participants. The CRF will be used to record data for all participants. Basic patient information, results of all examinations, chemotherapy programs used, AEs observed, and follow-up results will be recorded in a timely and truthful manner. These data will be held by both our department and the sponsor, and cannot be modified.
All participants will be enrolled in the final analysis regardless of whether they withdraw at any point. A descriptive statistical analysis will be performed for most of the study variables. The mean, median, standard deviation, maximum, and minimum will be calculated for quantitative variables, and the absolute and relative frequency, ratio, and CI calculated for qualitative and ranked variables.
The statistical analysis will be carried out by a biostatistician at the Center of Evidence-Based Medicine and Clinical Epidemiology, and the data will be analyzed statistically using SPSS software (version 15.0; SPSS Inc., Chicago, IL, USA). The ITT population, which will include all randomized patients, will be used for efficacy analysis. In addition, a per-protocol analysis will be performed on the efficacy endpoint. The ORRs, 1-year survival rate, and toxicity will be compared for the two groups using Fisher’s exact test, and the survival curve will be analyzed using the Kaplan-Meier method and log-rank test. A two-tailed test will be used for all statistics. P < 0.05 will be considered significant, and 95% confidence intervals will be calculated.
Lung cancer is the most common cancer worldwide, with NSCLC accounting for 85% of cases . Over the past 20 years, the 5-year survival rate for lung cancer has remained low (about 15%) . Over half of patients with NSCLC present with regional lymphatic and/or distant metastasis (stage IIIB and IV) at time of diagnosis, highlighting the need for new strategies to improve the prognosis of this disease .
Liposomal paclitaxel is a new formulation composed of paclitaxel packaged with liposomes, which has favorable pharmacokinetic properties including significant prolongation of elimination half-life and mean retention time, and an apparently larger volume of distribution in vivo. In particular, the dramatically higher drug concentration in the lymph nodes compared with the current paclitaxel formulations indicates that patients with NSCLC with regional lymphatic metastasis may benefit from this new drug. Because doublet chemotherapy composed of cisplatin and gemcitabine has commonly been recommended as first-line therapy for patients with advanced NSCLC [4, 22, 23], we have designed this open-label RCT to assess whether liposomal paclitaxel plus cisplatin (LP) is superior to gemcitabine plus cisplatin (GP) in efficacy (both short-term and long-term efficacy) and safety (toxicity).
This study will be the first RCT to investigate whether first-line therapy with liposomal paclitaxel can improve the prognosis of patients with NSCLC with regional lymphatic metastasis. The results of this study may provide a new chemotherapy regimen for clinicians and promote new trials to focus on patients with NSCLC with regional lymphatic metastasis.
Currently, 57 patients have been enrolled and randomized for this trial, and recruitment is ongoing.
Case report form
Gemcitabine and cisplatin
Liposomal paclitaxel and cisplatin
National Cancer Institute Common Toxicity Criteria
Non-small cell lung cancer
Objective response rate
Response Evaluation Criteria in Solid Tumor
Upper limit of normal
white blood cell count
World Health Organization.
We are grateful to the Center of Evidence-Based Medicine and Clinical Epidemiology for their statistical assistance during the study. This study is being supported by a grant from the Nanjing LUYE Pharmaceutical Co., Ltd. .
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516.View ArticlePubMed
- Ma Q, Liu D, Guo Y, Shi B, Song Z, Tian Y: Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2). Zhongguo Fei Ai Za Zhi. 2010, 13: 342-348.PubMed
- Sihoe AD, Yim AP: Lung cancer staging. J Surg Res. 2004, 117: 92-106. 10.1016/j.jss.2003.11.006.View ArticlePubMed
- Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado A, Azagra P, Jimenez U: Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol. 2003, 21: 3207-3213. 10.1200/JCO.2003.12.038.View ArticlePubMed
- Fisher MD, D'Orazio A: Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594). Clin Lung Cancer. 2000, 2: 21-22. 10.1016/S1525-7304(11)70620-9.View ArticlePubMed
- Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002, 346: 92-98. 10.1056/NEJMoa011954.View ArticlePubMed
- Davidoff AJ, Tang M, Seal B, Edelman MJ: Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010, 28: 2191-2197. 10.1200/JCO.2009.25.4052.View ArticlePubMed
- Straubinger RM, Arnold RD, Zhou R, Mazurchuk R, Slack JE: Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res. 2004, 24: 397-404.PubMed
- Prieto Garcia A, PinedadelaLosa F: Immunoglobulin E-mediated severe anaphylaxis to paclitaxel. J Investig Allergol Clin Immunol. 2010, 20: 170-171.PubMed
- Cabanes A, Briggs KE, Gokhale PC, Treat JA, Rahman A: Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol. 1998, 12: 1035-1040.PubMed
- Guo W, Johnson JL, Khan S, Ahmad A, Ahmad I: Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study. Anal Biochem. 2005, 336: 213-220. 10.1016/j.ab.2004.09.046.View ArticlePubMed
- Yan F, Li L, Deng Z, Jin Q, Zheng H: Paclitaxel-liposome loaded microbubbles for ultrasound-triggered drug delivery in vitro and in vivo. J Acoust Soc Am. 2012, 131: 3366-View Article
- Zeng X, Li Z, Hou M: [A randomized clinical trial on the clinical efficacy and toxicities of single-agent paclitaxel liposome versus paclitaxel liposome plus oxaliplatin as first-line chemotherapy for advanced non-small cell lung cancer in elderly patients]. Zhongguo Fei Ai Za Zhi. 2012, 15: 84-89.PubMed
- Zeng SY, Li L, Zhong ML, Jiang W, Wu YY, Liu Y: [A randomized controlled trial of two chemotherapy regimens (paclitaxel liposome combined with platinum and paclitaxel combined with platinum) in concurrent chemoradiotherapy for cervical carcinoma]. Zhonghua Zhong Liu Za Zhi. 2011, 33: 517-519.PubMed
- Li JH, Li B, Jiang HR, Zhong MZ: [Weekly regimen of paclitaxel liposome combined with cisplatin and 5-fluorouracil continuous infusion in the treatment of advanced gastric carcinoma]. Zhonghua Zhong Liu Za Zhi. 2011, 33: 229-231.PubMed
- Stathopoulos GP, Antoniou D, Dimitroulis J, Michalopoulou P, Bastas A, Marosis K, Stathopoulos J, Provata A, Yiamboudakis P, Veldekis D: Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann Oncol. 2010, 21: 2227-2232. 10.1093/annonc/mdq234.PubMed CentralView ArticlePubMed
- Zhang Q, Huang XE, Gao LL: A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. Biomed Pharmacother. 2009, 63: 603-607. 10.1016/j.biopha.2008.10.001.View ArticlePubMed
- Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG: CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012, 10: 28-55. 10.1016/j.ijsu.2011.10.001.View ArticlePubMed
- Tsuchida Y, Therasse P: Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol. 2001, 37: 1-3. 10.1002/mpo.1154.View ArticlePubMed
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.View ArticlePubMed
- Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.View ArticlePubMed
- Grigorescu A, Ciuleanu T, Firoiu E, Muresan DR, Teodorescu G, Basson BR: A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC). Lung Cancer. 2007, 57: 168-174. 10.1016/j.lungcan.2007.03.010.View ArticlePubMed
- Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000, 18: 122-130.PubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.